
TOKYO -- A Chinese lab attempting to patent the use of anti-flu drug Avigan for the treatment of COVID-19 is facing pushback in Japan, where the medicine was originally developed.
Fujifilm intellectual property cited as reason to 'reject' Beijing lab's application
TOKYO -- A Chinese lab attempting to patent the use of anti-flu drug Avigan for the treatment of COVID-19 is facing pushback in Japan, where the medicine was originally developed.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.